2016
DOI: 10.1016/j.bbmt.2016.01.019
|View full text |Cite
|
Sign up to set email alerts
|

A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33 + Acute Myeloid Leukemia

Abstract: Myeloablative conditioning and allogeneic hematopoietic stem cell transplant (alloHSCT) in children with acute myeloid leukemia (AML) in first complete remission (CR1) may be associated with significant acute toxicity and late effects. Reduced-intensity conditioning (RIC) and alloHSCT in children is safe, feasible, and may be associated with less adverse effects. Gemtuzumab ozogamicin (GO) induces a response in 30% of patients with CD33+ relapsed/refractory AML. The dose of GO is significantly lower when combi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
23
0

Year Published

2017
2017
2025
2025

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 22 publications
(23 citation statements)
references
References 53 publications
0
23
0
Order By: Relevance
“…HLA typing was performed using intermediate resolution for Class I A and B, and high resolution for Class I C, Class II, DRB1, and HLA‐DQB1. Typing was performed using the sequence specific oligonucleotide and sequence specific primer methods, as we have previously described . The criteria for donor matching included 5–6/6 for MSD, 8–10/10 for unrelated donor PBSC/BM, and 4–6/6 loci for unrelated umbilical CB and 3–6/6 for related CB.…”
Section: Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…HLA typing was performed using intermediate resolution for Class I A and B, and high resolution for Class I C, Class II, DRB1, and HLA‐DQB1. Typing was performed using the sequence specific oligonucleotide and sequence specific primer methods, as we have previously described . The criteria for donor matching included 5–6/6 for MSD, 8–10/10 for unrelated donor PBSC/BM, and 4–6/6 loci for unrelated umbilical CB and 3–6/6 for related CB.…”
Section: Methodsmentioning
confidence: 99%
“…Toxicity was graded according to the Common Terminology Criteria for Adverse Events version 4.0 . Relapse was defined by morphological and/or radiological evidence of malignant disease at any site; time to relapse was measured as the time interval between alloSCT and relapse, with censoring at death.…”
Section: Methodsmentioning
confidence: 99%
See 2 more Smart Citations
“…The results of these trials suggest the advantage of using GO in bridge therapy before alloSCT with other cytostatics. 9,10 Promising results were achieved with GO applied in AML relapse after stem cell transplantation (SCT) therapy. On September 1, 2017, the U.S. Food and Drug Agency (FDA) approved GO for treatment in adults with newly diagnosed CD33+ AML.…”
Section: High Molecular Mass Drugsmentioning
confidence: 99%